Actively Recruiting
Chemotherapy Combined with Immunotherapy and Targeted Therapy in Cholangiocarcinoma
Led by Second Affiliated Hospital, School of Medicine, Zhejiang University · Updated on 2025-02-06
300
Participants Needed
1
Research Sites
38 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study aims to validate the efficacy and safety of GP/GEMOX combined with PD-1/L1 inhibitors and TKI agents in patients with advanced cholangiocarcinoma through a multicenter, retrospective study to guide clinical practice.
CONDITIONS
Official Title
Chemotherapy Combined with Immunotherapy and Targeted Therapy in Cholangiocarcinoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histologically or radiologically confirmed intrahepatic cholangiocarcinoma
- Initially treated with gemcitabine and cisplatin or oxaliplatin (GP/GEMOX) or combined with PD-1/L1 and TKI inhibitors
You will not qualify if you...
- Direct surgery after hospitalization
- Initial treatment combined with local therapies such as radiotherapy, radiofrequency, particle implantation, or TACE
- Initial treatment involving other comprehensive therapeutic regimens
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
2nd Affiliated Hospital, School of Medicine, Zhejiang University
Hangzhou, Zhejiang, China, 310009
Actively Recruiting
Research Team
W
Weilin Wang, PHD
CONTACT
Y
Yuan Ding, PHD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here